From literature data, the acute and chronic GLP-1 RA therapy in addition to standard HF therapy in NYHA class III/IV patients results in a significant improvement of LVEF, of peak oxygen consumption, of 6MWT, and of the quality of life score [39, 40]. The gene discussed is GCG; the disease is hydrops fetalis.